Mylan and the EpiPen: Greed is Good?
AUGUST 29, 2016
Future Proof, MD
Mylan N.V. is an American-Dutch pharmaceutical company founded in 1961 in White Sulphur Springs, West Virginia. Currently the company’s American headquarters is hosted in Canonsburg, PA. Mylan acquired the rights to market and distribute the EpiPen line of epinephrine autoinjectors in America from Merck in a 2007 deal.
- In 2007, the EpiPen (2-pak) wholesaled for $100.
- Starting in 2009, Mylan began increasing the price of the EpiPen (2-pak). The latest price hike came in May 2016 from $461 to $609, sparking widespread public outcry.
- In the same period of time, the profit margin on the EpiPen increased from 9% to 55%.
- In the same period of time, Mylan CEO Heather Bresch’s compensation increased from $2.5 million to nearly $19 million.
- In 2015, EpiPen accounted for $1.5 Billion in sales for Mylan and 40% of its profits.
- Outside of the US, where the distribution of EpiPens is not controlled by Mylan, the price of the EpiPen remains relatively affordable. For example, in France, the EpiPen (2-pak) costs $85. And just to the north, Canadians pay ~$100 for a single EpiPen injector.
- In the week since the EpiPen controversy became public, Mylan’s stock (NASDAQ: MYL) has dropped 11.27%.
The Mylan EpiPen controversy is just the latest in a series of stories that seemingly represent corporate greed gone haywire. Companies hiking prices for their products is nothing new. It is often justified by the rising cost of doing business, but occasionally simply represents an attempt at juicing profits. Here are 2 parallels in the food & beverage industry:
- Whole Foods Market (NASDAQ: WFM) generated a lot of controversy when they tried to charge $5.99 for asparagus water. Here is my favorite TV comedian John Oliver taking a swing at the company:
- Starbucks (NASDAY: SBUX) have continually hiked prices on its drinks, most recently in July 2016. This is despite the fact that coffee bean prices have dropped a whopping 35% in the last 2 years.
In summary, Mylan was simply exercising its pricing power in an industry it excels in, not unlike Costco leaving American Express for Visa. In Mylan’s case, there was no way they could have known in advance that this was going to be straw that broke the camel’s back. As a physician investor, you may be attracted to healthcare companies given your background and training. But I would caution you to be aware of the “headline risks” involved, especially with highflying biotech stocks.
So is greed good? Yes and no. Just like how a little anxiety motivates you to study for an exam but too much anxiety may completely paralyze you, a healthy amount of greed motivates drug companies to develop new life-saving technologies, but too much of it will give you Mylan.